
Opinion|Videos|August 7, 2024
EMBARK Study: ADT in Nonmetastatic Castration-Sensitive Prostate Cancer
Stephen Freedland, MD, reviews findings from the EMBARK study, which investigated enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery
4
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
5













